Technical Analysis for EVFM - Evofem Biosciences, Inc.

Grade Last Price % Change Price Change
grade B 5.54 0.54% 0.03
EVFM closed up 0.54 percent on Wednesday, September 18, 2019, on 76 percent of normal volume.

Earnings due: Sep 27

*** please verify all earnings dates ***
0 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical EVFM trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Upper Bollinger Band Walk Strength 0.54%
Upper Bollinger Band Walk Strength 2.97%
Upper Bollinger Band Touch Strength 2.97%
Upper Bollinger Band Touch Strength 0.64%
Pocket Pivot Bullish Swing Setup -3.99%
Above Upper BB Strength -3.99%
Upper Bollinger Band Touch Strength -3.99%
Crossed Above 20 DMA Bullish 4.92%

Older signals for EVFM ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Read My Charts!
Configure default chart indicators
EVFM Chart by TradingView
Basic chart:
Profile
Neothetics Inc is a clinical-stage pharmaceutical company developing therapeutics for the aesthetic market. Its product is a novel injectable treatment for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients.
Pharmaceutical Obesity
Is EVFM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Sep 11 What Type Of Shareholder Owns Evofem Biosciences, Inc.'s (NASDAQ:EVFM)?
Sep 5 Evofem Biosciences (EVFM) Investor Presentation - Slideshow
Aug 26 Evofem Bio completes mid-stage AMPREVENCE trial for prevention of chlamydia and gonorrhea in women
Aug 26 Evofem Biosciences Completes Phase 2b 'AMPREVENCE' Trial of Amphora for Prevention of Chlamydia and Gonorrhea in Women
Aug 22 Evofem Biosciences to Present at Upcoming Healthcare Conferences
Aug 16 Evofem To Bring A Unique Product To Growing Market
Aug 10 Evofem Biosciences, Inc. (EVFM) CEO Saundra Pelletier on Q2 2019 Results - Earnings Call Transcript
Aug 8 PDL Biopharma Inc (PDLI) Q2 2019 Earnings Call Transcript
Aug 8 PDL BioPharma (PDLI) Q2 Earnings Top Mark, Revenues Fall Y/Y
Aug 8 Edited Transcript of EVFM earnings conference call or presentation 6-Aug-19 3:00pm GMT
See more EVFM news...
Indicators
Indicator Value
52 Week High 7.24
52 Week Low 3.16
Average Volume 30,689
200-Day Moving Average 4.5357
50-Day Moving Average 5.1249
20-Day Moving Average 5.2803
10-Day Moving Average 5.3895
Average True Range 0.3318
ADX 14.37
+DI 22.3565
-DI 16.4728
Chandelier Exit (Long, 3 ATRs ) 4.9046
Chandelier Exit (Short, 3 ATRs ) 5.7454
Upper Bollinger Band 5.7293
Lower Bollinger Band 4.8313
Percent B (%b) 0.79
BandWidth 17.006609
MACD Line 0.0961
MACD Signal Line 0.0661
MACD Histogram 0.03
Fundamentals Value
Market Cap 76.61 Million
Num Shares 13.8 Million
EPS -0.74
Price-to-Earnings (P/E) Ratio -7.49
Price-to-Sales 0.00
Price-to-Book 2.76
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.14
Resistance 3 (R3) 6.12 5.90 6.04
Resistance 2 (R2) 5.90 5.75 5.91 6.01
Resistance 1 (R1) 5.72 5.65 5.74 5.74 5.97
Pivot Point 5.50 5.50 5.51 5.51 5.50
Support 1 (S1) 5.32 5.35 5.34 5.34 5.11
Support 2 (S2) 5.10 5.25 5.11 5.07
Support 3 (S3) 4.92 5.10 5.04
Support 4 (S4) 4.94